OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

Acquisition of full T-cell effector function and memory differentiation requires appropriate costimulatory signals, including ligation of the costimulatory molecule OX40 (TNFRSF4, CD134). Tumors often grow despite the presence of tumor-specific T cells and establish an environment with weak costimulation and immune suppression. Administration of OX40 agonists has been shown to significantly increase the survival of tumor-bearing mice and was dependent on the presence of both CD4 and CD8 T cells during tumor-specific priming. To understand how OX40 agonists work in mice with established tumors, we developed a model to study changes in immune cell populations within the tumor environment. We show here that systemic administration of OX40 agonist antibodies increased the proportion of CD8 T cells at the tumor site in three different tumor models. The function of the CD8 T cells at the tumor site was also increased by administration of OX40 agonist antibody, and we observed an increase in the proportion of antigen-specific CD8 T cells within the tumor. Despite decreases in the proportion of T regulatory cells at the tumor site, T regulatory cell function in the spleen was unaffected by OX40 agonist antibody therapy. Interestingly, administration of OX40 agonist antibody caused significant changes in the tumor stroma, including decreased macrophages, myeloid-derived suppressor cells, and decreased expression of transforming growth factor-beta. Thus, therapies targeting OX40 dramatically changed the tumor environment by enhancing the infiltration and function of CD8 T cells combined with diminished suppressive influences within the tumor.

[1]  T. Ratliff,et al.  Defects in the Acquisition of CD8 T Cell Effector Function after Priming with Tumor or Soluble Antigen Can Be Overcome by the Addition of an OX40 Agonist1 , 2007, The Journal of Immunology.

[2]  Wenda Gao,et al.  OX40 costimulation turns off Foxp3+ Tregs. , 2007, Blood.

[3]  M. Croft,et al.  Cooperation between CD4 and CD8 T cells for anti‐tumor activity is enhanced by OX40 signals , 2007, European journal of immunology.

[4]  L. Kemény,et al.  Repeated epicutaneous exposures to ovalbumin progressively induce atopic dermatitis‐like skin lesions in mice , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[5]  A. Weinberg,et al.  Anti‐OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses , 2007, European journal of immunology.

[6]  B. Kwon,et al.  Functional Dichotomy between OX40 and 4-1BB in Modulating Effector CD8 T Cell Responses1 , 2006, The Journal of Immunology.

[7]  Tomoko Fujita,et al.  Functional characterization of OX40 expressed on human CD8+ T cells. , 2006, Immunology letters.

[8]  E. Jaffee,et al.  OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen1 , 2006, The Journal of Immunology.

[9]  C. Divino,et al.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. , 2006, Cancer research.

[10]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Blay,et al.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner , 2005, The Journal of experimental medicine.

[12]  M. Croft,et al.  OX40 and Bcl-xL Promote the Persistence of CD8 T Cells to Recall Tumor-Associated Antigen1 , 2005, The Journal of Immunology.

[13]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[14]  R. Vile,et al.  Gene Therapy to Manipulate Effector T Cell Trafficking to Tumors for Immunotherapy 1 , 2005, The Journal of Immunology.

[15]  M. Colombo,et al.  Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. , 2005, Blood.

[16]  Ximing J. Yang,et al.  Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. , 2005, Cancer research.

[17]  E. Butcher,et al.  Role for CXCR6 in Recruitment of Activated CD8+ Lymphocytes to Inflamed Liver1 , 2005, The Journal of Immunology.

[18]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[19]  J. Brayer,et al.  Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.

[20]  K. Sugamura,et al.  Distinct Roles for the OX40-OX40 Ligand Interaction in Regulatory and Nonregulatory T Cells1 , 2004, The Journal of Immunology.

[21]  W. Alvord,et al.  gp100209–2M Peptide Immunization of Human Lymphocyte Antigen-A2+ Stage I-III Melanoma Patients Induces Significant Increase in Antigen-Specific Effector and Long-Term Memory CD8+ T Cells , 2004, Clinical Cancer Research.

[22]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[23]  A. Weinberg,et al.  Engagement of OX40 Enhances Antigen-Specific CD4+ T Cell Mobilization/Memory Development and Humoral Immunity: Comparison of αOX-40 with αCTLA-41 , 2001, The Journal of Immunology.

[24]  J. Drazba,et al.  Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor1 , 2001, The Journal of Immunology.

[25]  A. Weinberg,et al.  Induction of Anti-Mammary Cancer Immunity by Engaging the OX-40 Receptor in Vivo , 2001, Breast Cancer Research and Treatment.

[26]  A. Weinberg,et al.  OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo. , 2001, Cellular immunology.

[27]  E. Kunkel,et al.  Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. , 2001, The Journal of clinical investigation.

[28]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[29]  R. Ronca,et al.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. , 2000, Blood.

[30]  T. Ishiwata,et al.  Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis , 2000 .

[31]  M. Croft,et al.  The OX40 Costimulatory Receptor Determines the Development of CD4 Memory by Regulating Primary Clonal Expansion1 , 2000, The Journal of Immunology.

[32]  Shu-Hsia Chen,et al.  Gr-1+ Myeloid Cells Derived from Tumor-Bearing Mice Inhibit Primary T Cell Activation Induced Through CD3/CD28 Costimulation1 , 2000, The Journal of Immunology.

[33]  G. Alvord,et al.  Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.

[34]  A. Weinberg,et al.  Danger and OX40 Receptor Signaling Synergize to Enhance Memory T Cell Survival by Inhibiting Peripheral Deletion1 , 2000, The Journal of Immunology.

[35]  R. Locksley,et al.  Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). , 1999, Journal of immunology.

[36]  M. Bachmann,et al.  OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. , 1999, Immunity.

[37]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[38]  T. Whiteside.  Signaling defects in T lymphocytes of patients with malignancy , 1999, Cancer Immunology, Immunotherapy.

[39]  D. Lo,et al.  Tumor antigens are constitutively presented in the draining lymph nodes. , 1999, Journal of immunology.

[40]  A. Weinberg,et al.  Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. , 1999, Journal of immunology.

[41]  Yuetsu Tanaka,et al.  Expression and function of OX40 ligand on human dendritic cells. , 1997, Journal of immunology.

[42]  J. Leonetti,et al.  Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte‐macrophage colony‐stimulating factor and contained CD34+ natural suppressor cells , 1997, International journal of cancer.

[43]  K. Sakaguchi,et al.  Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. , 1995, Journal of immunology.

[44]  L. Filgueira,et al.  The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor‐infiltrating lymphocytes , 1994, International journal of cancer.

[45]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Kristin A. Hogquist,et al.  T cell receptor antagonist peptides induce positive selection , 1994, Cell.

[47]  M. Croft,et al.  Response of naive antigen-specific CD4+ T cells in vitro: characteristics and antigen-presenting cell requirements , 1992, The Journal of experimental medicine.

[48]  S. Rosenberg,et al.  In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. , 1989, Journal of the National Cancer Institute.

[49]  M. Awwad,et al.  Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell- mediated immunity , 1988, The Journal of experimental medicine.

[50]  I. Bursuker,et al.  Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells , 1984, The Journal of experimental medicine.

[51]  I. Bursuker,et al.  Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity , 1984, The Journal of experimental medicine.